Product Description
Mechanisms of Action: NOS Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Arginox
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Myocardial Infarction|Shock, Cardiogenic
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2005-000412-27 |
TRIUMPH Study | P3 |
Completed |
Shock, Cardiogenic|Myocardial Infarction |
2007-08-22 |
2025-07-04 |
Treatments |
|
NCT00112281 |
ARG-CS3-001 | P3 |
Terminated |
Myocardial Infarction|Shock, Cardiogenic |
None |
2019-03-21 |
Treatments |